The Multiplex Function of Nitric Oxide in (Auto)immunity by Bogdan, Christian
 
1361
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/05/1361/05 $2.00
Volume 187, Number 9, May 4, 1998 1361–1365
http://www.jem.org
 
Commentary
 
The Multiplex Function of Nitric Oxide in (Auto)immunity
 
By Christian Bogdan
 
From the Institute of Clinical Microbiology, Immunology and Hygiene, University of Erlangen,
D-91054 Erlangen, Germany
 
S
 
tudy of the role of nitric oxide (NO) in mammalian or-
ganisms has a history of complexities. When eukaryotic
cells were demonstrated to generate NO from the ami-
 
noacid 
 
l
 
-arginine, we were first stunned and then fasci-
nated by the idea that a molecule with such a simple struc-
ture exerts messenger functions and regulates complex life
processes. Soon, however, we had to learn that there are at
least three different isoforms of nitric oxide synthases (NOS),
which all catalyze the same redox reaction, but differ in
biochemical and structural properties, output of NO, func-
tion, distribution, and regulation (1, 2). The introduction
of the acronyms ncNOS, iNOS, and ecNOS helped us to
memorize that the type 1 NOS is constitutively expressed
 
in neurons, where its activity is regulated by Ca
 
2
 
1
 
 gradients
and is critical for neurotransmission and learning; that the
type 2 NOS is transcriptionally induced by cytokines, is in-
dependent of elevations of calcium, and is prototypically
expressed in inflammatory macrophages, which makes them
cytotoxic against microbial pathogens and tumor cells; and
that the type 3 isoform is found as a constitutive enzyme in
the endothelial layer of blood vessels, thereby regulating
vascular tone and adhesion of circulating blood cells. Of
course, it was not long before this simplified conception of
a benign and host-protective NO world was challenged by
the discovery of harmful effects of NO such as neurotoxic-
ity, reperfusion injury, and severe hypotension during en-
dotoxic shock (1, 2).
For immunologists in particular, iNOS turned out to be
both friend and foe: on the one hand iNOS-derived NO
conveys protection against many (but by no means all) in-
tracellular bacteria and parasites, helps to fight several viral
infections, and is implicated in the control of malignancies
(3–6). On the other hand iNOS might also promote tumor
angiogenesis and metastasis (7, 8), and (i)NOS-dependent
tissue destruction and/or disease has been seen in several
rodent autoimmunity models, such as experimental allergic
encephalitis (EAE) and uveitis (EAU), inflammatory arthritis,
and immune complex glomerulonephritis (9–14). Now, a
number of recent studies, published in this and other jour-
nals, again extend our ideas of NO function in (auto)im-
munity and infectious diseases, as highlighted below.
 
Protective Functions of iNOS in EAE, EAU, and Interstitial
Nephritis.
 
A frequently proposed cascade for the develop-
ment of organ-specific autoimmune disease invokes the in-
duction and expansion of Th1 in response to microbial an-
 
tigens and IL-12, which secrete interferon IFN-
 
g
 
 and
thereby activate macrophages and other effector cells for
the production of tissue-damaging molecules such as reac-
tive oxygen intermediates or NO. Several parts of this con-
cept have been repeatedly challenged, particularly in the
EAE mouse model, which shares some similarities with hu-
man multiple sclerosis. In mice in which EAE was induced
via immunization with myelin basic protein (MBP) com-
bined with microbial adjuvants, it has been uniformly
shown that IFN-
 
g
 
 is not only dispensible for the develop-
ment of encephalitis, but clearly protects against disease
progression or relapses in susceptible mice and contributes
to the resistance of strains in which EAE cannot be elicited
(15, 16). Segal et al. recently reported in this journal that
the induction of EAE in IFN-
 
g
 
2
 
/
 
2
 
 mice can be prevented
by the simultaneous administration of anti–IL-12 antibod-
ies and that IL-12
 
2
 
/
 
2
 
 mice are completely resistant to dis-
ease development, most likely due to the expansion of a
MBP nonspecific CD4
 
1
 
 T cell population that produces
IL-10, counterregulates the encephalitogenic (EAE effec-
tor) T cells, and is itself subjected to control by IL-12.
Lymph node cells from anti–IL-12–treated and immunized
mice were unable to transfer the disease to naive recipients,
and splenocytes from naive donors treated with anti–IL-12
suppressed the development of EAE in immunized recipi-
ents (17). The above findings argue for a disease-protective
role of IFN-
 
g
 
 and a disease-promoting function of endoge-
nous IL-12 that becomes overt in the absence of endoge-
nous IFN-
 
g
 
. In both cases the cytokine effect might be
mediated by iNOS-derived NO. Segal et al. observed high
levels of TNF-
 
a
 
 and iNOS mRNA in the spinal cords of
MBP-immunized C57BL/6 IFN-
 
g
 
2
 
/
 
2
 
 mice, which were
markedly reduced after treatment with anti–IL-12 (17).
This is compatible with but certainly does not prove the
idea that iNOS/NO contributes to the IFN-
 
g
 
–indepen-
dent disease-promoting effect of IL-12. In contrast, in
IFN-
 
g
 
1
 
/
 
1
 
 PL/J mice, the pharmacologic inhibition or ge-
netic deletion of iNOS was associated with an increased in-
cidence and/or enhanced severity of EAE induced by im-
munization with MBP (18). Comparable results were also
obtained by Kahl et al. (19). This strongly suggests a pro-
tective, antiinflammatory role of iNOS. Possible underly-
ing mechanisms include known functions of iNOS/NO
such as the suppression of T cell proliferation and Th1 cy-
tokine production, the reduction of leukocyte adhesion
and infiltration, the inhibition of other tissue-damaging
pathways (e.g., NADPH oxidase), the scavenging of super-
oxide, and/or the apoptosis of macrophages or (encephali-
togenic) T cells (for review see references 5 and 20; 21–24).
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However, the picture on the role of iNOS/NO in ro-
dent EAE is far from uniform. The results obtained by
Fenyk-Melody et al. (18) are in accordance with three
studies in the rat EAE model, but at first glance contradict
another set of studies with different strains of mice, in
which treatment with aminoguanidine (an NOS inhibitor
with relative selectivity for iNOS), D609 (an inhibitor of
activity of phosphatidylcholine-specific phospholipase C),
2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-
3-oxide (c-PTIO; an NO scavenger), or uric acid (a puta-
tive scavenger of peroxinitrite) ameliorated the severity of
EAE. The results of these studies are summarized in Table
1, and as recently proposed by Gold et al. (25), are best rec-
onciled by the assumption that iNOS can exhibit two dif-
ferent roles in EAE, either of which might prevail depend-
ing on the mode of induction: when EAE is induced by
the injection of MBP-specific T cells (adoptive transfer
model), the production of NO triggered by the encephali-
togenic T cells appears to be primarily tissue-damaging,
whereas in EAE directly induced by immunization with
MBP the main function of NO appears to be counterregu-
latory and disease-limiting. There is certainly an impact of
the species (rat versus mouse) and the mouse strain as illus-
trated by the disparate results obtained by Brenner et al.
(13). As to the findings of Hooper et al. (26) (Table 1), it is
important to bear in mind that phosphatidylcholine-phos-
pholipase C is the key enzyme of a signaling pathway that
has many intracellular targets with no specificity for the in-
duction of iNOS. The potent protective effect of uric acid
clearly deserves further clarification, especially because the
NO levels in the brains of mice treated with uric acid were
prominently increased rather than decreased (26). In view
of the discrepancies between the studies listed in Table 1, it
would be wise to avoid the use of NOS inhibitors, which
are already known to suppress general stimulatory pathways
(e.g., D609), exhibit functions unrelated to NOS (e.g.,
aminoguanidine, which inhibits copper-containing amine
oxidases, catalase, and the formation of advanced glycosyla-
tion end-products, and generates hydrogen peroxide in the
presence of Cu
 
2
 
1
 
; 27 and references therein) or show little
or no selectivity for the inducible isoform of NOS (e.g.,
the 
 
l
 
-arginine analogues L-NAME and L-NMMA, which
impair iNOS, ncNOS, and ecNOS activity and cause hy-
pertension and loss of weight; 28, 29, and references
therein). As a final point, iNOS-positive cells in the CNS
from diseased SJL mice (or in the brain from multiple scle-
rosis patients) have been identified as members of the mac-
rophage/microglia as well as astrocyte lineages (26, 30), but
it remains speculative to ascribe the opposing functions of
NO to these different cell types. 
Protective and disease-mediating roles of iNOS/NO
have also been discovered in two other autoimmune dis-
ease models, supporting the existence of a general princi-
ple. In the rat model of autoimmune interstitial nephritis,
treatment with 
 
l
 
-
 
N
 
6
 
-(1-iminoethyl)-lysine (L-NIL), a po-
tent and relatively selective inhibitor of iNOS, intensified
the renal injury (29). In EAU induced by immunization
with interphotoreceptor retinoid binding protein in adju-
vants, genetic deletion of iNOS or low-dose (50 mg/kg)
treatment with L-NAME delayed the onset and decreased
 
Table 1.
 
Effect of (i)NOS inhibition on the course of EAE
 
*
 
Species/Strain Inhibitor used
Effect on MBP-
induced disease
Effect on adoptively
transferred disease Reference
Lewis rats AG exacerbation not tested 32
L-NMMA no effect no effect
L-NAME no effect no effect
Lewis rats L-NMMA exacerbation not tested 33
L-NAME exacerbation not tested
Lewis rats AG not tested protection 12
Lewis rats L-NIL exacerbation protection 25
SJL mice AG not tested protection 11
SJL mice iNOS antisense ODN not tested protection 41
SWXJ-14 mice D609 protection not tested 26
c-PTIO protection not tested
uric acid protection not tested
(PL/J 
 
3
 
 SJL) F
 
1
 
 mice AG protection protection 13
PL/J mice AG exacerbation not tested 18
(129SvEv 
 
3
 
 PL/J 
 
3
 
 PL/J mice iNOS gene deletion exacerbation not tested 18
(129SvEv 
 
3
 
 C57BL/6) F
 
2
 
 mice iNOS gene deletion exacerbation not tested 19
AG, aminoguanidine; L-NAME, L-nitroarginine-methyl-ester; L-NMMA, L-monomethyl-arginine; L-NIL, L-iminoethyl-lysine; c-PTIO, 2-(4-
carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; ODN, oligodeoxynucleotide.
 
*
 
Modified from reference 25. 
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the severity of the ocular inflammation, whereas high-dose
treatment with L-NAME was previously seen to exacer-
bate the disease (14 and references therein; 31). These find-
ings point to a proinflammatory effect of iNOS in EAU
and illustrate the difficulty of interpreting results obtained
with the nonselective NOS inhibitor L-NAME. Similar to
the EAE model, EAU will develop in the absence of en-
dogenous IFN-
 
g
 
, and endogenous IFN-
 
g
 
 at the systemic
level appears to play a disease-limiting, protective role
(31a). Whether this latter effect also involves iNOS remains
to be investigated.
 
Counterprotective Functions of iNOS in Infectious Diseases.
 
iNOS/NO does not have universal antimicrobial potency.
First, several microbial species (e.g., 
 
Salmonella
 
, 
 
Mycobate-
rium avium/intracellulare
 
, 
 
Mycobacterium tuberculosis
 
) exhibit
intrinsic or strain-dependent resistance to NO, the molecu-
lar basis of which has begun to be unravelled. Second, in a
number of infections (e.g., 
 
M. avium
 
 infections, influenza
virus pneumonia, rabies, or borna virus encephalitis) ex-
pression of iNOS was clearly correlated with disease progres-
sion, arguing for a proinflammatory, autotoxic, and/or im-
munosuppressive function of NO (for review see references
2, 4, 6). So far, iNOS appeared to be either protective or
counterprotective for the course and outcome of a given
infectious disease. A clear exception to this rule has now
been demonstrated by Khan et al. in the C57BL/6 mouse
model of 
 
Toxoplasma gondii
 
 infection (34). After low dose
infection (20 cysts), 50% of iNOS
 
1
 
/
 
1
 
 mice survived beyond
day 90, whereas all iNOS
 
2
 
/
 
2
 
 mice had died by day 30,
which is in agreement with the results from previous stud-
ies (35 and references therein). In contrast, when the parasite
inoculum was increased to 50–100 cysts, all iNOS
 
1
 
/
 
1
 
 mice
died within 12 d, but most of the iNOS
 
2
 
/
 
2
 
 mice survived
for 
 
$ 
 
21 d. Histology revealed extensive fatty degeneration
of the liver and necrosis of the distal ileum in iNOS
 
1
 
/
 
1
 
mice, whereas both organs were intact in iNOS
 
2
 
/
 
2
 
 or ami-
noguanidine-treated wild-type mice. However, the numbers
of parasites in the brain and liver of iNOS
 
2
 
/
 
2
 
 mice were
3- or 15-fold higher compared to wild-type controls. Thus,
iNOS appears to account for the tissue damage seen in the
gut and liver, but simultaneously confers some protection
against the parasites in the liver and the brain. As intestinal
necrosis in 
 
T. gondii
 
-infected wild-type mice can also be
prevented by anti–IFN-
 
g
 
 treatment (36), the prominent
induction of iNOS in the small bowel is likely to be due to
the hyperexpression of IFN-
 
g
 
.
 
Cytokine Regulation by iNOS In Vivo.
 
There is consid-
erable evidence from in vitro experiments that iNOS-
derived NO can modulate the cytokine response of mac-
rophages, T cells, endothelial cells, and fibroblasts. This might
be due to its capacity to activate and inactivate ion channels, G
proteins, protein tyrosine kinases, Janus kinases, redox sen-
sitive kinases, and transcription factors (for review see refer-
ences 37, 38). Two recent studies highlight the possibility
that NO assumes a similar regulatory function also in vivo. 
Hierholzer et al. (39) analyzed the function of iNOS in a
murine model of hemorrhagic shock. They report that the
deletion of the iNOS gene in the mouse or pharmacologic
inhibition of iNOS by L-NIL in the rat reduced the degree
of tissue injury in liver and lung, which in control animals
occurred within 4 h of resuscitation. The authors further
demonstrate that in the absence of iNOS the activation of
two transcription factors (NF-
 
k
 
B and Stat3) was signifi-
cantly reduced in the lung and liver. The same was true for
the expression of IL-6 and G-CSF, which are critical com-
ponents of the inflammatory response following resuscita-
tion from shock and are thought to be controlled by NF-
 
k
 
B
and Stat3. Although the stimulus for the induction of
iNOS in this model remains to be elucidated, the data sup-
port the conclusion that iNOS serves both tissue-damaging
and cytokine regulatory functions in this model.
In the mouse model of cutaneous leishmaniosis, iNOS
was previously identified as a critical antileishmanial mech-
anism which was thought to start operating only when
macrophages become activated by IFN-
 
g
 
–secreting CD4
 
1
 
T cells (for review see references 4, 6). A recent study now
shows that the expression of iNOS is not restricted to the
T-cell–dependent late phase of infection, but is also an im-
portant component of the innate response of the host,
where it is focally induced by IFN-
 
a
 
/
 
b
 
 within the first 24 h
of infection (40). In iNOS
 
2
 
/
 
2
 
 or L-NIL–treated wild-type
mice, there is a 30-fold reduction of the baseline expression
of IL-12 p40 mRNA, an almost complete lack of the up-
regulation of IFN-
 
g
 
, markedly reduced cytotoxic activity
of NK cells, and an upregulation of the macrophage-inhib-
itory cytokine TGF-
 
b
 
 in the 
 
Leishmania major
 
–infected skin
Figure 1. Scheme of putative interactions of iNOS, cytokines, and NK
cells during the innate response to L. major. In iNOS1/1 mice, early ex-
pression of iNOS is due to IFN-a/b, which is induced by L. major. NO
itself can kill Leishmania, but also mediates (directly or via expression of
IL-12 and maintaining responsiveness to IL-12) the functional maturation
of NK cells (cytotoxic activity and IFN-g production). IFN-g, in turn,
suppresses the production of TGF-b, mediates parasite containment (i.e.,
prevents spreading of L. major from the site of infection to visceral or-
gans), and presumably further enhances the expression of iNOS. Asterisks
denote processes that are dependent on endogenous NO. 
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and/or lymph node. Furthermore, in the absence of iNOS
activity the parasites will disseminate (from the skin and
lymph node to the spleen, liver, bone marrow, and lung),
which is secondary to the lack of IFN-
 
g
 
. In vitro, lymph
node cells from day 1–infected mice fail to respond to IL-12
in the absence of iNOS (Diefenbach, A., M. Röllinghoff,
and C. Bogdan, manuscript in preparation), and macro-
phages from iNOS
 
2
 
/
 
2
 
 mice are refractory to the downreg-
ulation of TGF-
 
b
 
1 production by IFN-
 
g
 
. Thus, the earlier
recognized antileishmanial activity of iNOS during the late
phase of infection now contrasts with a regulatory function
of NO during the innate response to 
 
L. major
 
, the potential
sequence of which is summarized in Fig. 1.
 
Conclusions.
 
The role of iNOS/NO in the immune
system comprises both regulatory and effector functions.
This first category includes immunosuppressive effects
(e.g., inhibition of lymphocyte proliferation) and the mod-
ulation of the cytokine response. The second category in-
cludes immunopathologic effects (e.g., tissue destruction)
and immunoprotective activities (e.g., killing of microbial
pathogens or apoptosis of autoreactive T cells). The results
discussed above illustrate that NO functions are not mutu-
ally exclusive. In fact, the prevailing data strongly suggest
that signaling and effector functions of NO can operate in
vivo in parallel, in a synergistic or antagonistic manner.
Clearly, the mere detection of iNOS expression correlating
directly or inversely with a clinical phenotype no longer al-
lows us to draw firm conclusions as to its function. This
makes it difficult to predict the effect of NO donors and
iNOS inhibitors in a given disease. On the other hand, it is
exactly this complexity that should encourage further stud-
ies on the pro- and antiinflammatory effects of NO, its cel-
lular and tissue distribution, and the relationship between
NO function and concentration in the microenvironment
of inflammatory lesions. In this context it is also time to an-
alyze the role of the neuronal and endothelial isoform of
NOS in the immune system. No, there is no end yet to
NO in immunology.
 
I thank Drs. A. Diefenbach, C. Nathan, M. Röllinghoff, and S. Stenger for their helpful comments and
apologize to those authors whose work I could not cite directly due to the limits of space.
The preparation of the manuscript and the conduct of some of the studies reviewed were supported by the
Deutsche Forschungsgemeinschaft (SFB263, A5).
Address correspondence to Christian Bogdan, Institut für klinische Mikrobiologie, Immunologie, und Hy-
giene, Friedrich-Alexander-Universität Erlangen-Nürnberg, Wasserturmstrasse 3, D-91054 Erlangen,
Germany. Phone: 011-49-9131-852647; Fax: 011-49-9131-852573; E-mail: christian.bogdan@mikro-
bio.med.uni-erlangen.de
 
Received for publication 24 February 1998.
 
Note added in proof.
 
 The results reported by Fenyk-Melody et al. (18) were recently confirmed by U.C. Suhr-
bucher et al. using iNOS-deficient 129SvEv 
 
3
 
 C57BL/6 mice (
 
Eur. J. Immunol
 
. 1998. 28:1332–1338).
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